Management of RAASi-associated hyperkalemia in patients with cardiovascular disease

Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). However, RAASi may induce hyperkalemia, a potentially life...

ver descrição completa

Detalhes bibliográficos
Autor principal: Silva-Cardoso, José (author)
Outros Autores: Brito, Dulce (author), Frazão, João Miguel (author), Ferreira, Aníbal (author), Bettencourt, Paulo (author), Branco, Patrícia (author), Fonseca, Cândida (author)
Formato: review
Idioma:eng
Publicado em: 2021
Assuntos:
Heart failure with reduced ejection fraction
Hyperkalemia
Novel potassium binders
RAASi optimization
Renin–angiotensin–aldosterone system inhibitors
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
Texto completo:http://hdl.handle.net/10362/113799
País:Portugal
Oai:oai:run.unl.pt:10362/113799

Texto Completo

http://hdl.handle.net/10362/113799

Registros relacionados